Geron Corp (NASDAQ:GERN)

CAPS Rating: 3 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Recs

0
Player Avatar robyjer (85.85) Submitted: 2/13/2007 1:30:13 PM : Outperform Start Price: $8.06 GERN Score: -79.51

Once the dems start putting forth their agenda, this co may be way ahead on the stem cell research.

Featured Broker Partners


Advertisement